Switching to tacrolimus in heart transplant recipients with recurrent rejection episodes;Konverze na tacrolimus u pacientu po transplantaci srdce s rekurentní rejekcí

Cor et Vasa

Volumn 48, Issue 12, 2006, Pages 421-425

  Dufková, Blanka ^a   Málek, Ivan ^a   Vymětalová, Yevheniya ^a  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

Author keywords

Acute cellular rejection; Cyclosporin A; Heart transplantation; Tacrolimus

Indexed keywords

AZATHIOPRINE; CHOLESTEROL; CORTICOSTEROID; CREATININE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; CARDIAC GRAFT REJECTION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG CHOICE; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GRAFT RECIPIENT; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LEUKOPENIA; MALE; RECURRENT DISEASE; SYSTOLIC BLOOD PRESSURE;

EID: 33845910379     PISSN: 00108650     EISSN: None     Source Type: Journal    
DOI: 10.33678/cor.2006.135     Document Type: Article

References (23)

1. Málek I. Transplantace srdce, pohled kardiologa. Praha: Triton. 2004:103.
2. Kubo SH, Naftel DC, Mills RM Jr, et al. Risk factors for late reccurent rejection after heart transplantation. J Heart Lung Transplant 1995;14:409-18.
3. Yamani MH, Yousufuddin M, Starling RC, et al. Does acute cellular rejection correlate with cardiac allograft vasculopathy? J Heart Lung Transplant 2004;23: 272-6.
4. Segovia J. Update on cardiac allograft vasculopathy. Curr Opin Organ Transplant 2002;7:240-51.
5. Reichenspurner H. Overwiew of tacrolimus-based immunosuppression after heart or lung transplantation. J Heart Lung Transplant 2005;24;119-30.
6. Gote T, Kino T, Hatanaka H, et al. FK 506: historical perspectives. Transplant Proc 1991;23:2713-7.
7. Jiang H, Wynn C, Pan F, Ebbs A, Ericsson LM, Kobayashi M. Tacrolimus and cyclosporine differ in their capacity to overcome ongoing allograft rejection as a result of their differential abilities to inhibit interleukin-10 production. Transplantation 2002;73: 1808-17.
8. Keogh A. Calcineurin inhibitors in heart transplantation. J Heart Lung Transplant 2004;23:S202-S206.
9. Špinarová L. Hypertenze po transplantaci srdce. Vnitř Lék 1999;45:555-8.
10. Billingham ME, Cary NR, Hammond ME, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: heart rejection study group. Heart Transplant 1990;9:587-93.
11. Mentzer RM Jr, Jahania MS, Lasley RD. The U. S. multicenter FK506 study group. Tacrolimus as a rescue immunosuppressant after heart and lung transplantation. Transplantation 1998;65:109-13.
12. Onsager DR, Canver CC, Jahania MS, et al. Efficacy of tacrolimus in the treatment of refractory rejection in heart and lung transplant recipient. J Heart Lung Transplant 1999;18:448-55.
13. Yamani MH, Starling RC, Pelegrin D, et al. Efficacy of tacrolimus in patiens with steroid-resistant cardiac allograft cellular rejection. J Heart Lung Transplant 2000;19:337-42.
14. Bonis MD, Reynolds L, Barros J, Madden BP. Tacrolimus as a rescue immunosuppressant after heart transplantation. J Thorac Cardiovasc Surg 2001;19:690-5.
15. Tailor DO, Barr ML, Radovancevic B, et al. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transplant 1999; 18:336-45.
16. Christians U, Jacobsen W, Benet LZ, et al. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet 2002;41:813-51.
17. Christians U, Jacobsen W, Floren LC, et al. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl koenzyme A reduktase inhibitors on transplant pacients: are the statins mechanistically similar? Pharmacol Ther 1998;80:1-34.
18. Hošková L, Málek I, Šedivý J, Podzimková M, Kautzner J, Pirk J. Lékové interakce cyklosporinu A. Cor Vasa 2002;44:481-6.
19. Widimský J. Poškození svalů při léčbě inhibitory HMG CoA reduktázy - statiny. Cor Vasa 2003;45:376-86.
20. Lemahieu WPD, Hermann M, Asberg A, et al. Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus. Am J Transplant 2005; 5:2236-43.
21. Reichart B, Meiser B, Vigano M, et al. European multicenter tacrolimus (FK506) heart pilot study: one-year results - European tacrolimus multicenter heart study group. J Heart Lung Transplant 1998;17:775-81.
22. Meiser BM, Uberfuhr P, Fuchs A, et al. Single-center randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of acute myocardial rejection. J Heart Lung Transplant 1998;17:782-8.
23. Trulock EP, Edwards LB, Taylor DO, et al. Registry of the international society for heart and lung transplantation: twenty-second official adult lung and heart-lung transplant report. J Heart Lung Transplant 2005;24: 956-67.